生物活性

• 描述CP-547632 is a potent inhibitor of the VEGFR-2 and basic fibroblast growth factor (FGF) kinases (IC50 11 and 9 nM, respectively). It is selective relative to epidermal growth factor receptor, platelet-derived growth factor, and other related TKs. It also inhibits VEGF-stimulated autophosphorylation of VEGFR-2 in a whole cell assay with an IC50 value of 6 nM.
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT00074854	Lung Neoplasms	Phase 1 Phase 2	Completed	-	United States, California ... more >> Pfizer Investigational Site Greenbrae, California, United States, 94904 Pfizer Investigational Site San Mateo, California, United States, 94402 Pfizer Investigational Site San Pablo, California, United States, 94806 United States, Florida Pfizer Investigational Site Tampa, Florida, United States, 33612-9497 United States, Louisiana Pfizer Investigational Site Covington, Louisiana, United States, 70433 Pfizer Investigational Site Metairie, Louisiana, United States, 70002 Pfizer Investigational Site Metairie, Louisiana, United States, 70006 Pfizer Investigational Site New Orleans, Louisiana, United States, 70115 United States, Massachusetts Pfizer Investigational Site Boston, Massachusetts, United States, 02215 United States, New York Pfizer Investigational Site Stony Brook, New York, United States, 11794 United States, Pennsylvania Pfizer Investigational Site Philadelphia, Pennsylvania, United States, 19111 United States, Tennessee Pfizer Investigational Site Gallatin, Tennessee, United States, 37066 Pfizer Investigational Site Hermitage, Tennessee, United States, 37076 Pfizer Investigational Site Lebanon, Tennessee, United States, 37087 Pfizer Investigational Site Murfreesboro, Tennessee, United States, 37130 Pfizer Investigational Site Nashville, Tennessee, United States, 37203 Pfizer Investigational Site Nashville, Tennessee, United States, 37205 Pfizer Investigational Site Nashville, Tennessee, United States, 37207 Pfizer Investigational Site Nashville, Tennessee, United States, 37211 Pfizer Investigational Site Smyrna, Tennessee, United States, 37167 Collapse <<
  NCT00096239	Fallopian Tube Cancer ... more >> Ovarian Cancer Primary Peritoneal Cavity Cancer Collapse <<	Phase 2	Completed	-	United States, California ... more >> Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California, United States, 90095-1781 Collapse <<
  NCT00074867	Ovarian Neoplasms ... more >> Peritoneal Neoplasms Fallopian Tube Neoplasms Collapse <<	Phase 2	Completed	-	United States, California ... more >> Pfizer Investigational Site Los Angeles, California, United States, 90095 Pfizer Investigational Site Santa Monica, California, United States, 90404 United States, Maryland Pfizer Investigational Site Baltimore, Maryland, United States, 21237 United States, Massachusetts Pfizer Investigational Site Boston, Massachusetts, United States, 02114 Pfizer Investigational Site Boston, Massachusetts, United States, 02115 Pfizer Investigational Site Boston, Massachusetts, United States, 02215 United States, New York Pfizer Investigational Site New York, New York, United States, 10016 Canada, Ontario Pfizer Investigational Site Hamilton, Ontario, Canada, L8V 5C2 Canada Pfizer Investigational Site Quebec, Canada, G1R 2J6 Collapse <<

• 参考文献

• [1] Cohen RB, Langer CJ, et al. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cancer Chemother Pharmacol. 2007 Jun;60(1):81-9.

  [2] Wakelee HA, Schiller JH. Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. Clin Lung Cancer. 2005 Sep;7 Suppl 1:S31-8. Review.